What's actually happening when acid reflux strikes, why it matters over the long term, and what the evidence says about treating it
Acid reflux — or gastro-oesophageal reflux disease (GORD) — is one of the most common conditions a GP sees. At its heart it is a mechanical problem: stomach acid travelling in the wrong direction.
When you swallow, food passes down the oesophagus (the gullet) into the stomach, passing through a muscular valve called the lower oesophageal sphincter. This valve is supposed to open to let food through, then close tightly to keep stomach contents — including acid — where they belong. In people with acid reflux, this valve doesn't close properly. Stomach acid leaks back up into the oesophagus, causing the burning sensation most people know as heartburn.
Reflux of some stomach contents is actually normal — it happens briefly after every meal in everyone. The problem arises when it becomes frequent or persistent enough to cause symptoms or damage the lining of the oesophagus. That is when it becomes GORD.
GORD affects between 20–28% of the adult UK population — making it one of the most common reasons people visit their GP or pharmacist. Many more experience occasional symptoms without meeting the full clinical definition.
Source: Guts UK · Kennedy & Jones, Aliment Pharmacol Ther 2000 · Dent et al., Gut 2005Acid reflux is not one thing. It sits on a spectrum. At the mild end are people with occasional heartburn, well-managed with antacids or simple lifestyle changes. At the more severe end is persistent GORD with oesophageal inflammation, which if left untreated can lead to long-term complications including a condition called Barrett's oesophagus.
Several factors make reflux more likely. The most important are:
Increased abdominal pressure pushes stomach contents upwards, weakening the sphincter over time.
Part of the stomach slides up through the diaphragm into the chest, disrupting the sphincter mechanism.
Weakens the lower oesophageal sphincter and reduces saliva production, which normally neutralises acid.
Hormonal changes relax the sphincter, and the growing uterus increases abdominal pressure.
NSAIDs, calcium channel blockers, nitrates, and some antidepressants can worsen reflux.
Large meals, eating late at night, and foods including fatty food, coffee, alcohol, and chocolate can all trigger symptoms.
For most people, acid reflux is uncomfortable but manageable — a nuisance that flares up after a large meal or a late night. But for a significant number, it becomes a chronic condition that affects sleep, quality of life, and — over the long term — carries real clinical risks.
The five reasons it matters:
Up to one in four UK adults experience regular heartburn or regurgitation. Most manage symptoms with over-the-counter antacids without ever speaking to a doctor. This means the condition is widely underdiagnosed, and people who would benefit from more effective treatment — or from investigation to rule out complications — often don't get it.
Repeated acid exposure inflames the oesophageal lining (oesophagitis). In more severe cases this leads to erosions, ulceration, and scarring. A narrowing of the oesophagus (stricture) can develop, making swallowing progressively difficult. These are not rare edge cases — they are the expected consequence of sustained, untreated reflux.
In a subset of people with chronic GORD, the normal oesophageal lining is replaced by a different cell type — a change called Barrett's oesophagus. It is thought to affect around 10–15% of people with longstanding symptomatic GORD, though many cases are never diagnosed because it causes no additional symptoms of its own.
Barrett's oesophagus is a precancerous condition. A meta-analysis of 57 studies and over 58,000 patient-years of follow-up found that approximately 0.33% of people with Barrett's oesophagus develop oesophageal adenocarcinoma each year — equivalent to around 1 in 300 per year. For people with short-segment Barrett's, the risk is lower still, at around 0.19% per year. This risk needs to be kept in proportion: for any individual, the absolute annual risk remains low. But it is the reason the NHS monitors people with confirmed Barrett's through regular endoscopic surveillance. (Desai TK et al., Gut 2012)
Heartburn is the classic symptom, but GORD presents in other ways that can be confusing. A chronic cough — especially one that is worse at night — is a well-recognised but frequently missed presentation of reflux. The same applies to hoarseness, a persistent sensation of a lump in the throat (globus), and non-cardiac chest pain. In some people these atypical symptoms occur without any heartburn at all.
This matters because these presentations are often investigated and treated for other causes — sometimes for years — before reflux is considered.
These are known as alarm features. They do not necessarily mean cancer, but in UK practice they warrant prompt investigation — typically an urgent endoscopy — to rule out serious underlying pathology. 111 or urgent GP access exists for exactly this situation. NICE describes these as warranting urgent referral regardless of age. (NICE CG184)
GORD is usually diagnosed clinically — that is, from the history alone. A GP who hears a clear description of heartburn (burning pain behind the breastbone, worse after meals, worse lying flat, relieved by antacids) in an otherwise well patient without alarm features will typically diagnose GORD and start treatment without needing any tests.
NICE guideline CG184 describes lifestyle advice as part of any GORD consultation alongside medication. The evidence for lifestyle modification varies — some changes have stronger evidence than others — but as a general principle, the following are the changes NICE describes:
| Lifestyle change | Rationale |
|---|---|
| Weight loss where overweight | Strongest evidence of any lifestyle intervention. Reduces abdominal pressure and improves LOS function |
| Raising the head of the bed by 15–20cm | Reduces nocturnal reflux by using gravity to keep acid in the stomach |
| Avoiding eating within 3 hours of bedtime | Gives the stomach time to empty before lying flat |
| Smaller, more frequent meals | Reduces the volume of stomach contents at any one time |
| Reducing alcohol, caffeine, and fatty foods | These relax the LOS or stimulate acid production in many people |
| Smoking cessation | Smoking weakens the LOS and impairs saliva production |
| Avoiding tight clothing around the abdomen | Increases abdominal pressure |
For most people with symptomatic GORD, medication provides effective relief. NICE describes a structured approach, starting with the most effective first-line option:
| Medication | How it works | Typical use |
|---|---|---|
| Antacids / Alginates e.g. Gaviscon, Rennies |
Neutralise existing acid; alginates form a raft on top of stomach contents to prevent reflux | Mild, infrequent symptoms; immediate relief; safe in pregnancy |
| H2 Receptor Antagonists (H2RAs) e.g. famotidine |
Reduce acid production by blocking histamine receptors in stomach cells | Mild-moderate symptoms; useful when PPIs not tolerated |
| Proton Pump Inhibitors (PPIs) e.g. omeprazole, lansoprazole |
Block the proton pump — the final mechanism of acid production — giving potent, sustained acid suppression | Moderate-severe symptoms; first-line for GORD; 4–8 week initial course, lowest effective dose long-term |
Most people with GORD do not need an endoscopy. NICE describes endoscopy as warranted when alarm features are present, when symptoms persist despite adequate treatment, or when there is clinical suspicion of Barrett's oesophagus. Routine endoscopy simply to diagnose uncomplicated GORD is not part of the recommended pathway.
Where Barrett's oesophagus is found at endoscopy, the person enters a surveillance programme — typically repeat endoscopy every two to five years depending on severity, to check for any progression towards dysplasia or early cancer.
For people with confirmed GORD whose symptoms are well-controlled on PPIs but who do not wish to take medication long-term, or who cannot tolerate acid suppression, laparoscopic fundoplication is available. This keyhole procedure tightens the lower oesophageal sphincter by wrapping the top of the stomach around it. NICE describes it as a reasonable option in appropriately selected patients. Long-term outcomes are good in most cases, though some people experience difficulty swallowing (dysphagia) in the period after surgery.
A Cochrane systematic review by Khan M, Santana J, Donnellan C, Preston C, and Moayyedi P (2007) assessed 134 randomised trials involving 35,978 participants with reflux oesophagitis. PPIs produced significantly higher rates of oesophagitis healing compared with H2 receptor antagonists (RR 0.51, 95% CI 0.44 to 0.59) and were also more effective than placebo (RR 0.22, 95% CI 0.15 to 0.31). H2RAs were superior to placebo but substantially less effective than PPIs. This established the PPI as the clear first-line pharmacological treatment — a position confirmed by all subsequent guidelines.
The LOTUS trial was a randomised controlled trial comparing laparoscopic antireflux surgery (fundoplication) with long-term esomeprazole treatment in 554 patients with chronic GORD, followed for up to five years. Both treatments produced similar rates of remission of GORD symptoms at five years — around 85–90%. Surgery had a slightly higher initial remission rate but was associated with more side effects in the post-operative period including dysphagia and bloating. The trial concluded that both approaches are effective long-term management options, with the choice depending on patient preference, surgical risk, and tolerance of medication.
A prospective cohort study using data from the Nurses' Health Study (over 10,000 women) found that weight gain was strongly associated with increased frequency of GORD symptoms, and that weight loss reduced symptoms — even in women who were not obese. Participants who lost more than 3.5kg had significantly lower odds of frequent symptoms. This is the clearest evidence that for overweight patients, weight loss is the most effective lifestyle intervention available for GORD — more so than dietary exclusions of individual trigger foods. ⚑
A large systematic review and meta-analysis pooling data from 57 studies and over 58,000 Barrett's oesophagus patients found that the annual incidence of oesophageal adenocarcinoma in people with Barrett's was approximately 0.33% per year — equivalent to roughly 1 in 300 people per year. This is substantially lower than earlier estimates, which had led to concern about over-investigation. The risk is concentrated in people with longer Barrett's segments, higher grade dysplasia, male sex, and older age. For people with non-dysplastic Barrett's and short segments, the risk is particularly low — a finding that has influenced surveillance frequency guidelines. ⚑
A large analysis using UK Biobank data (over 63,000 PPI users compared with H2RA users) confirmed a range of associations between long-term PPI use and adverse outcomes including chronic kidney disease, enteric infections, and nutrient deficiencies. However, the absolute risk increases were modest, and the study — like most of this literature — was observational, meaning confounding is difficult to exclude. People on long-term PPIs tend to be older and have more comorbidities than those on H2RAs. The overall clinical consensus is that PPIs are safe for appropriately indicated long-term use alongside periodic review, with the dose stepped down to the minimum needed. ⚑
Acid reflux is so common it is easy to dismiss. Most people have experienced heartburn at some point, and most of the time it resolves with simple measures. But for a significant minority, it is a persistent condition that can damage the oesophagus, disrupt sleep, and — over many years — create a small but real risk of serious complications.
The good news is that the treatment evidence is strong. PPIs, used correctly and at the right dose, are highly effective at relieving symptoms and healing oesophageal inflammation. Lifestyle changes — particularly weight loss — add meaningfully to this. Endoscopic surveillance can catch Barrett's oesophagus at a stage where it can be monitored and managed. And for people who want a medication-free long-term solution, surgery offers an effective alternative.
Frequent or persistent heartburn — and any alarm features — are a conversation for you to have with your GP or healthcare professional, not something to manage indefinitely with another packet of Gaviscon.
National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. NICE Clinical Guideline CG184. London: NICE; 2014 (last updated September 2024).
Guts UK Charity. Heartburn and Acid Reflux: Causes, Symptoms and Treatment. Guts UK Patient Information. 2024. Available at: gutscharity.org.uk
Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Alimentary Pharmacology & Therapeutics 2000;14(12):1589–1594. DOI: 10.1046/j.1365-2036.2000.00884.x
Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54(5):710–717. DOI: 10.1136/gut.2004.051821
Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. The Lancet 2006;367(9528):2086–2100. DOI: 10.1016/S0140-6736(06)68860-4
Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database of Systematic Reviews 2007;(2):CD003244. DOI: 10.1002/14651858.CD003244.pub2
Galmiche JP, Hatlebakk J, Attwood S, et al.; LOTUS Trial Collaborators. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011;305(19):1969–1977. DOI: 10.1001/jama.2011.626
Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Body-mass index and symptoms of gastroesophageal reflux in women. New England Journal of Medicine 2006;354(22):2340–2348. DOI: 10.1056/NEJMoa054391
Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61(7):970–976. DOI: 10.1136/gutjnl-2011-300730
Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019;365:l1580. DOI: 10.1136/bmj.l1580